Dashboard
Manage Tickers

OCULOCULAR THERAPEUTIX, INC

Nasdaq ocutx.com


$ 8.85 $ 0.11 (1.26 %)    

Tuesday, 20-Aug-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.15 $ -1.01 (-0.21 %)
DIA $ 408.54 $ -0.55 (-0.13 %)
SPY $ 558.65 $ -0.91 (-0.16 %)
TLT $ 98.68 $ 0.78 (0.8 %)
GLD $ 232.46 $ 0.85 (0.37 %)
$ 8.84
$ 8.71
$ 8.84 x 200
$ 8.85 x 536
$ 8.53 - $ 8.89
$ 2.00 - $ 11.31
721,749
na
1.47B
$ 1.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 03-11-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 03-06-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-05-2021 03-31-2021 10-Q
15 03-11-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-07-2020 06-30-2020 10-Q
18 05-08-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-10-2019 03-31-2019 10-Q
23 03-07-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 03-08-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-05-2017 03-31-2017 10-Q
31 03-10-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 03-10-2016 12-31-2015 10-K
36 11-10-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-15-2015 03-31-2015 10-Q
39 03-20-2015 12-31-2014 10-K
40 11-12-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

baird-maintains-outperform-on-ocular-therapeutix-lowers-price-target-to-17
Baird Maintains Outperform on Ocular Thera...
08/08/2024 12:00:18

Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and lowers the price target from $18...

ocular-therapeutix-cash-balance-of-4597m-as-of-june-30-2024-expected-to-fund-operations-into-2028
Ocular Therapeutix' Cash Balance Of $459.7...
08/07/2024 11:12:35

ocular-therapeutix-q2-2024-gaap-eps-026-misses-022-estimate-sales-16441m-beat-15824m-estimate
Ocular Therapeutix Q2 2024 GAAP EPS $(0.26...
08/07/2024 11:11:47

ocular-therapeutix-has-received-fda-written-response-that-phase-3-sol-r-trial-is-appropriate-for-use-as-the-companys-second-adequate-and-well-controlled-study-of-axpaxli-axitinib-intravitreal-implant-also-known-as-otx-tki-for-wet-age-related-macular-degeneration
Ocular Therapeutix Has Received FDA Writte...
08/07/2024 11:10:48

beyond-the-numbers-8-analysts-discuss-ocular-therapeutix-stock
Beyond The Numbers: 8 Analysts Discuss Ocu...
08/01/2024 18:05:41

hc-wainwright--co-reiterates-buy-on-ocular-therapeutix-maintains-14-price-target
HC Wainwright & Co. Reiterates Buy on Ocul...
08/01/2024 10:28:23

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $14 price target.

ocular-therapeutix-enrolls-first-patients-in-phase-3-sol-r-wet-amd-study
Ocular Therapeutix Enrolls First Patients ...
07/30/2024 11:46:58

ocular-therapeutix-to-present-late-breaking-abstract-of-helios-study-at-42nd-asrs-annual-scientific-meeting
Ocular Therapeutix To Present Late-Breakin...
07/10/2024 12:11:27

Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")))), a biopharmaceutical company committed to en...

piper-sandler-maintains-overweight-on-ocular-therapeutix-maintains-15-price-target
Piper Sandler Maintains Overweight on Ocul...
06/21/2024 17:42:42

Piper Sandler analyst Biren Amin maintains Ocular Therapeutix (NASDAQ:OCUL) with a Overweight and maintains $15 price target.

why-jabil-shares-are-trading-lower-by-8-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Jabil Shares Are Trading Lower By 8%? ...
06/20/2024 17:26:29

kb-home-reports-upbeat-earnings-joins-harrow-accenture-gilead-sciences-and-other-big-stocks-moving-higher-on-thursday
KB Home Reports Upbeat Earnings, Joins Har...
06/20/2024 14:21:23

this-skyworks-solutions-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday
This Skyworks Solutions Analyst Turns Bull...
06/20/2024 13:13:29

workday-to-rally-over-52-here-are-10-top-analyst-forecasts-for-thursday
Workday To Rally Over 52%? Here Are 10 Top...
06/20/2024 12:11:28

td-cowen-upgrades-ocular-therapeutix-to-buy-raises-price-target-to-11
TD Cowen Upgrades Ocular Therapeutix to Bu...
06/20/2024 09:46:30

TD Cowen analyst Tara Bancroft upgrades Ocular Therapeutix (NASDAQ:OCUL) from Hold to Buy and raises the price target from $...

why-ammo-shares-are-trading-lower-by-over-19-here-are-other-stocks-moving-in-fridays-mid-day-session
Why AMMO Shares Are Trading Lower By Over ...
06/14/2024 18:13:08

piper-sandler-maintains-overweight-on-ocular-therapeutix-maintains-15-price-target
Piper Sandler Maintains Overweight on Ocul...
06/14/2024 16:47:44

Piper Sandler analyst Joseph Catanzaro maintains Ocular Therapeutix (NASDAQ:OCUL) with a Overweight and maintains $15 price ...

hasbro-tutor-perini-arm-holdings-and-other-big-stocks-moving-higher-on-friday
Hasbro, Tutor Perini, Arm Holdings And Oth...
06/14/2024 14:29:19

deep-dive-into-ocular-therapeutix-stock-analyst-perspectives-6-ratings
Deep Dive Into Ocular Therapeutix Stock: A...
06/14/2024 12:01:06

hc-wainwright--co-reiterates-buy-on-ocular-therapeutix-maintains-14-price-target
HC Wainwright & Co. Reiterates Buy on Ocul...
06/14/2024 10:19:14

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $14 price target.

ocular-therapeutix-highlights-axpaxli-sol-1-enrollment-and-plans-repeat-dosing-study-in-wet-amd-announces-48-week-data-from-helios-npdr-study
Ocular Therapeutix Highlights AXPAXLI SOL-...
06/13/2024 20:10:44

151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7,...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION